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INTRODUCTION
In the 1970s and 1980s, the aminoglycoside antibiotics were a key antibiotic group in the treatment of serious Gram-negative infections.
With the introduction of new beta-lactam agents with pronounced Gram-negative activity during the 1980s, the use of aminoglycosides waned as the less toxic beta-lactams were increasingly used, and this trend continued into the early part of this century [1, 2] . The declining use of one or more of the aminoglycosides was frequently accompanied by observations of increasing susceptibility among key pathogens [3, 4] although this relationship has not held true in all studies [2] . We are now entering a time in which we are encountering rapidly increasing Gram-negative resistance to broad-spectrum beta-lactams including third and fourth generation cephalosporins, beta-lactam-betalactamase inhibitor combinations, and the carbapenems. This rising resistance is often mediated by extended-spectrum betalactamases (ESBL) and carbapenemases [5] [6] [7] .
Moreover, the Gram-negative pathogens producing these enzymes are often co-resistant to other important antibiotic classes such as the fluoroquinolones [7] [8] [9] . Because of this, it has been suggested by a number of studies that the use of aminoglycosides may be increasing as clinicians search for viable alternative therapies in treating infections with otherwise resistant Gram-negative pathogens [10] [11] [12] . The purpose of the present analysis was to assess the level of aminoglycoside use in adults at our institution from 2006 through 2012 and, during that same time period, the level of susceptibility of key Gram-negative pathogens to this antibiotic class. 
METHODS

RESULTS
Results for antibiotic usage and organism susceptibility for the years of interest are presented in Tables 1 and 2 Susceptibility of P. aeruginosa, E. coli and K. pneumoniae to these aminoglycosides did not change significantly over time either in the last few years of observation or compared to 1992.
While it has been suggested that there may be an increased interest and, therefore, use of [10] [11] [12] , neither our observations nor those stemming from analyses using a collection of academic medical centers' data support that theory [1, 2] . In fact, the latter two studies revealed diminishing use [2] . In the more recent of these two reports, reflecting use in 29 hospitals, an overall decline of 41% was reported from 2002 to 2009 [2] . Resistance to aminoglycoside antibiotics occurs through a number of mechanisms including enzymatic modification, decreased cellular penetration, active efflux and target site alterations with the former being most common [15] . On that basis, it is reasonable to consider aminoglycoside therapy for infections involving Gram-negative pathogens suspected of producing newer ESBLs or carbapenemases. However, the observation that such bacteria often carry resistance determinants to other antibiotic classes, including aminoglycosides, fluoroquinolones and folic acid inhibitors, may undermine that line of thinking [7] [8] [9] . The fact that other broadspectrum antibiotic exposure may represent a risk factor for acquisition and infection by such organisms only exacerbates the challenge of identifying suitable therapy [16] .
The positive aspect of our findings is perhaps that susceptibility of these key Gram-negative pathogens seems to be stable, at least at our institution. This may well be due to low levels of use in comparison with other Gram-negative agents. In fact, tobramycin remains the most active of our routinely tested antibiotics against P. aeruginosa while the vast majority of E. coli and K. pneumoniae are susceptible to amikacin. reporting susceptibility data for a variety of bacteria including our organisms of interest collected and tested from 1999 through 2008, noted increasing aminoglycoside resistance [17] . That study collected isolates associated with serious infections from hospitals across the United States [17] . While levels of aminoglycoside use cannot be ascertained, that report emphasizes the importance of each hospital determining its own circumstances with regard to aminoglycoside susceptibility patterns [17] .
The current study is not without limitations. As this is a single-center analysis, our results cannot be extrapolated to other hospitals or healthcare settings. We limited our investigation to P. aeruginosa, E. coli and K.
pneumoniae as they are all common causes of healthcare associated infections and are often multidrug resistant [18] . Obviously, a number of other Gram-negative and Gram-positive pathogens are also problematic, multidrug resistant causes of healthcare associated infections and were not considered here. 
